Trial Profile
A Phase II Open Label, Multi-Center Study With AVR118 in Anorectic Patients With Recurrent or Advanced Malignancies
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs AVR 118 (Primary)
- Indications Leukaemia; Lymphoma; Multiple myeloma; Solid tumours
- Focus Therapeutic Use
- 12 Mar 2019 Status changed from recruiting to discontinued.
- 07 Nov 2016 New trial record